SecProbe.io

CORRESP
1
filename1.htm

    Skadden, Arps, Slate, Meagher & Flom

    Partners

    Geoffrey
    Chan *

    Shu
    Du *

    Andrew
    L. Foster *

    Chi
    T. Steve Kwok *

    Edward
    H.P. Lam ¨*

    Haiping
    Li *

    Rory
    McAlpine ¨

    Jonathan
    B. Stone *

    Kai Sun

    Paloma P. Wang

    ¨
    (Also Admitted in England & Wales)

    *
    (Also Admitted in New York)

    世達國際律師事務所

    42/F, EDINBURGH TOWER, THE LANDMARK

    15 QUEEN’S
    ROAD CENTRAL, HONG KONG

    ________

    TEL: (852) 3740-4700

    FAX: (852) 3740-4727

    www.skadden.com

    AFFILIATE OFFICES

    -----------

    BOSTON

    CHICAGO

    HOUSTON

    LOS ANGELES

    NEW YORK

    PALO ALTO

    WASHINGTON, D.C.

    WILMINGTON

    -----------

    BEIJING

    BRUSSELS

    FRANKFURT

    LONDON

    MUNICH

    PARIS

    SÃO PAULO

    SEOUL

    SHANGHAI

    SINGAPORE

    TOKYO

    TORONTO

    November 14, 2022

    VIA EDGAR

    Ms. Kathryn Jacobson

    Mr. Robert Littlepage

    Mr. Kyle Wiley

    Mr. Jeff Kauten

    Division of Corporation Finance

    Office of Technology

    U.S. Securities and Exchange Commission

    100 F Street, NE

    Washington, D.C. 20549

Re: ECARX Holdings Inc. (CIK No. 0001861974)

Dear Ms. Jacobson, Mr. Littlepage, Mr. Wiley and Mr. Kauten,

On behalf of our client, ECARX Holdings Inc., a
foreign private issuer organized under the laws of the Cayman Islands (the “Company”), we thank the staff (the “Staff”)
of the Securities and Exchange Commission (the “Commission”) for the prompt review of the Amendment No.1 to the Company’s
registration statement on Form F-4 filed with the Commission on November 4, 2022 (the “Amendment No.1”) and submit
this letter setting forth the Company’s responses to the comments contained in the Staff’s letter dated November 9, 2022 with
respect to the Amendment No.1.

U.S. Securities and Exchange Commission

November 14, 2022

Page 2

Concurrently with the submission of this letter,
the Company is filing the Amendment No. 2 to the registration statement on Form F-4 (the “Amendment No. 2”) and certain
exhibits via EDGAR with the Commission.

The Staff’s comments are repeated below in
bold and are followed by the Company’s responses. We have included page references in the Amendment No. 2 where the language addressing
a particular comment appears. Capitalized terms used but not otherwise defined herein have the meanings set forth in the Amendment No.
2. In addition to the changes made in response to the Staff’s comments, the changes reflected in the Amendment No. 2 also include
the updated unaudited condensed financial information for the nine months ended September 30, 2022 for COVA Acquisition Corp. and the
corresponding updated pro forma financial information.

The Company endeavors to have the registration
statement declared effective as soon as practicable by November 18, 2022 and would be grateful for the Staff’s review and continued
support.

Recent Developments of ECARX, page 32

 1. We note your discussion of preliminary results for the quarter ended September 30, 2022. In order to provide a more balanced presentation,
please revise your presentation to also disclose your estimated expenses and net income/loss for the period in addition to your current
presentation of estimated revenue and cost of revenues.

In response to the Staff’s comment, the Company has
revised the disclosure on page 33 of the Amendment No. 2.

Regulation on Foreign Investment, page 232

 2. We note your statement that the research and manufacture of certain automobile devices in China falls within the encouraged category
for foreign investment. Please revise your filing to clarify the practical effect to you of this designation.

In response to the Staff’s comment, the Company has
revised the disclosure on page 217 of the Amendment No. 2.

Unaudited Pro Forma Condensed Combined Financial
Information Ownership, page 261

 3. Refer to Adjustment (E). Since the Lotus Note will be converted into 1,052,632 ECARX Class A ordinary shares at closing, please
include such shares among Total Ordinary Shares Outstanding at Closing (instead of a potential source of dilution).

U.S. Securities and Exchange Commission

November 14, 2022

Page 3

In response to the Staff’s comment, the Company has
revised the disclosure on page 262 of the Amendment No. 2 and has made corresponding revisions to disclosures on pages 16, 20-22, 38-40,
and 132-134 of the Amendment No. 2.

 4. Refer to Adjustment (G). We note hereunder and elsewhere in your filing that the Investor Notes will be converted into ECARX Class
A ordinary shares at a conversion price of US$11.50 per share (up to 5,652,174 ECARX Class A ordinary shares). However, it appears that
neither the conversion price nor the conversion shares are stipulated in the Investor Note Agreement (October 25, 2022) under Exhibit
10.23. Please cite your basis for the conversion terms, including any addendum to the subject agreement.

In response to the Staff’s comment, the Company has
revised the disclosure on page 263 of the Amendment No. 2 and has re-filed the Convertible Note Purchase Agreement under Exhibit 10.23
to the Amendment No. 2 to include the Form of Convertible Senior Note under Schedule 1 of the Convertible Note Purchase Agreement, which
stipulates the conversion price and other conversion terms for the Investor Notes.

Unaudited Pro Forma Combined Statement of Operations For the
Six Months Ended June 30, 2022, page 265

 5. We note your response to prior comments 1 and 2. It is unclear why the pro forma condensed combined statements of operations for
the interim period and the year ended December 31, 2021 do not include autonomous entity adjustments that would remove revenues and cost
of revenues associated with the businesses spun off to Hubei ECARX VIE, including but not limited to the Daimler contract (AI voice products
signed by Hubei ECARX on March 5, 2020), the Internet Map Service of Hubei ECARX, mapping activities and ICP License. Please revise and
provide clarifications in the accompanying notes, as appropriate.

In response to the Staff’s comment, the Company has
revised the disclosure on pages 271-272 of the Amendment No. 2. The Company respectfully advises the Staff that the Company has not generated any revenues from activities in association with the Internet
Map Service, mapping activities and ICP License, as they are still in research and development stage.

Adjustments to Unaudited Pro Forma Combined Statement of Operations
4. Loss per Share, page 272

 6. Refer to footnote (1). Please revise so that the Pro Forma Shares Outstanding to calculate Loss per Share are consistent with the
Total Ordinary Shares Outstanding at Closing on page 261. Please note that the shares underlying the Lotus Note and the strategic investments
that would be issued at closing would be considered outstanding and not contingently issuable that would have
been otherwise antidilutive.

U.S. Securities and Exchange Commission

November 14, 2022

Page 4

In response to the Staff’s comment,
the Company has revised the disclosure on page 274 of the Amendment No. 2.

Notes to Unaudited Condensed Consolidated Financial Statements
1. Summary of significant accounting policies (b) Reorganization, page F-66

 7. We note your response to prior comment 3. Please clarify in your disclosure that the temporary transfers to third parties that
were returned to you did not include the equity interests that led you to deconsolidate Hubei Dongjun Automotive Electronic Technology
Co., LTD and Suzhou Photon-Matrix Optoelectronics Technology Co. Ltd.

In response to the Staff’s comment, the Company has
revised the disclosure on page F-67 of the Amendment No. 2.

*        	*	        *

U.S. Securities and Exchange Commission

November 14, 2022

Page 5

If you have any questions regarding the Amendment
No. 2, please contact the undersigned by phone at +852 3740 4858 or via email at shu.du@skadden.com, or Brian Breheny by phone at +1 202
371 7180 or via email at brian.breheny@skadden.com.

    Very truly yours,

    /s/ Shu Du

    Shu Du

cc: Ziyu Shen, Chairman of the Board of Directors and Chief Executive Officer, ECARX Holdings Inc.

  Ramesh Narasimhan, Chief Financial Officer,
ECARX Holdings Inc.

Jun Hong Heng, Chairman, Chief Executive Officer and Chief
Financial Officer of COVA Acquisition Corp.

Peter X. Huang, Partner, Skadden, Arps,
Slate, Meagher & Flom LLP

Shu Du, Partner, Skadden, Arps, Slate, Meagher & Flom
LLP

Albert W. Vanderlaan, Partner, Orrick Herrington & Sutcliffe
LLP

Oliver Xu, Partner, KPMG Huazhen LLP